Acute Myeloid Leukemia (AML)
Symptoms, Doctors, Treatments, Advances & More

Acute Myeloid Leukemia (AML) Overview

Save information for later
Sign Up

Learn About Acute Myeloid Leukemia (AML)

View Main Condition: Leukemia

What is the definition of Acute Myeloid Leukemia (AML)?
Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor.
Who are the top Acute Myeloid Leukemia (AML) Local Doctors?
Elite in Acute Myeloid Leukemia (AML)
Dr. Mikkael A. Sekeres
Hematology Oncology | Hematology
Elite in Acute Myeloid Leukemia (AML)
Dr. Mikkael A. Sekeres
Hematology Oncology | Hematology
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mikkael Sekeres is a Hematologist Oncology specialist and a Hematologist practicing medicine in Miami, Florida. Dr. Sekeres is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sekeres is currently accepting new patients.

Elite in Acute Myeloid Leukemia (AML)
Elite in Acute Myeloid Leukemia (AML)
Referral may be required

The Arthur G. James Cancer Hospital And Richard J. Solove Research Institute

460 W 10th Ave, 
Columbus, OH 
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marcos De Lima is a Hematologist practicing medicine in Columbus, Ohio. Dr. De Lima is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. De Lima is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Myeloid Leukemia (AML)
Elite in Acute Myeloid Leukemia (AML)
Referral may be required

Novant Health Cancer Institute - Elizabeth (Hematology)

125 Queens Road, Suite 610, 
Charlotte, NC 
980-302-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Rizzieri is an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Rizzieri is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Graft. Dr. Rizzieri is currently accepting new patients.

View All Doctors
What are the latest Acute Myeloid Leukemia (AML) Clinical Trials?
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the gr...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological, Device
Study Phase: Phase 1

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center